Literature DB >> 19419416

Germ line MLH1 and MSH2 mutations in Taiwanese Lynch syndrome families: characterization of a founder genomic mutation in the MLH1 gene.

R Tang1, C Hsiung, J-Y Wang, C-H Lai, H-T Chien, L-L Chiu, C-T Liu, H-H Chen, H-M Wang, S-X Chen, L-L Hsieh.   

Abstract

This multicenter study evaluated the mutation spectrum and frequencies of the MLH1 and MSH2 genes and determined the occurrence of large genomic deletions in 93 unrelated Taiwanese families that fulfilled the Amsterdam criteria II by denaturing high-performance liquid chromatography analysis, DNA sequencing for aberrant chromatograms, and multiplex ligation-dependent probe amplification analysis. In total, 38 pathogenic mutations (10 large deletions and 28 point mutations or small deletion/insertions) in the MSH2 or MLH1 gene were identified in 61 of the 93 families (66%). Three of the 10 large deletions and 14 of the 28 point mutations or small insertions/deletions have not been reported elsewhere. Three mutations in the MLH1 gene, the MLH1c.1846_1848delAAG (5 families), deletion exons 11-15 (4 unrelated families), and MLH1c.793C>T (13 unrelated families), accounted for 35% of all cases with pathogenic mutations. Haplotype analysis indicated that mutant c.793C>T alleles were derived from two distinct common founders that might be inherited from a single ancestor of presumably Chinese origin. As a mutation detection strategy for Taiwanese Lynch syndrome patients, we recommend that diagnosis starts with screening for large genomic deletions and continues by screening for common mutations in exons 10 and 16 of the MLH1 gene prior to searching for small mutations in the remaining exons.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19419416     DOI: 10.1111/j.1399-0004.2009.01162.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  12 in total

1.  Characterization of germline mutations of MLH1 and MSH2 in unrelated south American suspected Lynch syndrome individuals.

Authors:  Mev Dominguez Valentin; Felipe Carneiro da Silva; Erika Maria Monteiro dos Santos; Bianca Garcia Lisboa; Ligia Petrolini de Oliveira; Fabio de Oliveira Ferreira; Israel Gomy; Wilson Toshihiko Nakagawa; Samuel Aguiar Junior; Mariana Redal; Carlos Vaccaro; Adriana Della Valle; Carlos Sarroca; Dirce Maria Carraro; Benedito Mauro Rossi
Journal:  Fam Cancer       Date:  2011-12       Impact factor: 2.375

2.  Clinical characterization and mutation spectrum in Caribbean Hispanic families with Lynch syndrome.

Authors:  Marcia Cruz-Correa; Yaritza Diaz-Algorri; Julyann Pérez-Mayoral; Wasilah Suleiman-Suleiman; Maria del Mar Gonzalez-Pons; Carlos Bertrán; Nicolás Casellas; Natalia Rodríguez; Sherly Pardo; Keyla Rivera; Rafael Mosquera; Segundo Rodriguez-Quilichini
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

Review 3.  Synonymous Variants: Necessary Nuance in Our Understanding of Cancer Drivers and Treatment Outcomes.

Authors:  Nayiri M Kaissarian; Douglas Meyer; Chava Kimchi-Sarfaty
Journal:  J Natl Cancer Inst       Date:  2022-08-08       Impact factor: 11.816

4.  Cancer risks and immunohistochemical profiles linked to the Danish MLH1 Lynch syndrome founder mutation.

Authors:  Christina Therkildsen; Anna Isinger-Ekstrand; Steen Ladelund; Anja Nissen; Eva Rambech; Inge Bernstein; Mef Nilbert
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

5.  A de novo germline MLH1 mutation in a Lynch syndrome patient with discordant immunohistochemical and molecular biology test results.

Authors:  Fabrice Airaud; Sébastien Küry; Isabelle Valo; Ingrid Maury; Dominique Bonneau; Olivier Ingster; Stéphane Bezieau
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

6.  Systematic study on genetic and epimutational profile of a cohort of Amsterdam criteria-defined Lynch Syndrome in Singapore.

Authors:  Yanqun Liu; Min Hoe Chew; Xue Wei Goh; Soo Yong Tan; Carol Tien Tau Loi; Yuen Ming Tan; Hai Yang Law; Poh Koon Koh; Choong Leong Tang
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

7.  TP53 Polymorphisms and Colorectal Cancer Risk in Patients with Lynch Syndrome in Taiwan: A Retrospective Cohort Study.

Authors:  Abram Bunya Kamiza; Ling-Ling Hsieh; Reiping Tang; Huei-Tzu Chien; Chih-Hsiung Lai; Li-Ling Chiu; Tsai-Ping Lo; Kuan-Yi Hung; Jeng-Fu You; Wen-Chang Wang; Chao A Hsiung; Chih-Ching Yeh
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

8.  DNA Methylation Identifies Loci Distinguishing Hereditary Nonpolyposis Colorectal Cancer Without Germ-Line MLH1/MSH2 Mutation from Sporadic Colorectal Cancer.

Authors:  Chung-Hsing Chen; Shih Sheng Jiang; Ling-Ling Hsieh; Reiping Tang; Chao A Hsiung; Hui-Ju Tsai; I-Shou Chang
Journal:  Clin Transl Gastroenterol       Date:  2016-12-15       Impact factor: 4.488

9.  Missense mutations of MLH1 and MSH2 genes detected in patients with gastrointestinal cancer are associated with exonic splicing enhancers and silencers.

Authors:  Ming Zhu; Hui-Mei Chen; Ya-Ping Wang
Journal:  Oncol Lett       Date:  2013-03-11       Impact factor: 2.967

10.  Risk Factors Associated with Colorectal Cancer in a Subset of Patients with Mutations in MLH1 and MSH2 in Taiwan Fulfilling the Amsterdam II Criteria for Lynch Syndrome.

Authors:  Abram Bunya Kamiza; Ling-Ling Hsieh; Reiping Tang; Huei-Tzu Chien; Chih-Hsiung Lai; Li-Ling Chiu; Tsai-Ping Lo; Kuan-Yi Hung; Chun-Yi Wang; Jeng-Fu You; Chao A Hsiung; Chih-Ching Yeh
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.